Ocuphire PharmaOCUP
OCUP
Delisted
About: Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Employees: 14
Financial journalist opinion
Neutral
PRNewsWire
5 months ago
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C. , Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company.
Positive
Benzinga
6 months ago
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
On Wednesday, Ocuphire Pharma, Inc. OCUP announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs).
Neutral
Business Wire
6 months ago
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for possible breaches of fiduciary duty and other violations of law in its transaction with Opus Genetics. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. In the transaction, Ocuphire will issue 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing stockholders of Opus Geneti.
Neutral
GlobeNewsWire
6 months ago
Ocuphire Pharma Announces Acquisition of Opus Genetics
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations
Neutral
GlobeNewsWire
6 months ago
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile
Neutral
GlobeNewsWire
7 months ago
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants.
Negative
Zacks Investment Research
8 months ago
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates
Ocuphire Pharma, Inc. (OCUP) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.
Neutral
GlobeNewsWire
8 months ago
Ocuphire Pharma to Present at Two Investor Conferences in August
FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that George Magrath, M.D., M.B.A., M.S., Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference, to take place in Boston, MA, August 14, 2024, and at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, to take place virtually, on August 15, 2024.
Neutral
GlobeNewsWire
9 months ago
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced it will participate in the Association for Research in Vision and Ophthalmology Special Interest Group (ARVO SIG) panel and the American Society of Retina Specialists (ASRS) 42 nd Annual Scientific Meeting, to highlight the potential of its lead oral candidate in development for diabetic retinopathy (DR).
Neutral
GlobeNewsWire
10 months ago
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company's lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit meeting June 25-27 in Boston.
Charts implemented using Lightweight Charts™